Hodgkin hastalığının standart tedavisinde rekombinant human granülosit koloni stimüle edici faktör kullanımı
Yükleniyor...
Dosyalar
Tarih
1998
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turgut Özal Tıp Merkezi Dergisi
Erişim Hakkı
Attribution 3.0 United States
Özet
The aim of this study was to evaluate the effectiveness of recombinant granulocyte colony stimulating factor (rhG-CSF) administered following cytotoxic chemotherapy in Hodgkin's disease. Total number of 26 courses of rhG-CSF were applied in 19 patients with Hodgkin's disease aged 15 to 61 (median 44) years. They received MOPP (Nitrogen Mustard, Vincritine, Procarbazine, Prednisone) chemotherapy every 28 days. rhG-CSF was given at a dose of 5^/kg daily and subcutaneously from day 2nd to 6th day 8th to 20h unless the neutrophil count exceeded 10.000/mm3, in which case rhG-CSF discontinued. The outcome was compared with 24 prognostically similar control patients treated with the same chemotherapy without rhG-CSF. Recovery of granulocyte counts above 1000/mm was significantly faster in the rhG-CSF treated group (3±0.72 days vs 7±0.81 days; p<0.001). The incidence of febrile neutropenia and empiric parenteral antibiotic use were lower in study patients (%36 vs %64 ; p<0.05). But there was no reduction in the incidence of documented infections. Full doses of chemotherapy could be given on time to 26/26 (%100) rhG-CSF patients but to only 18/24 (%75) controls (p<0.01). All patients tolerated cytokine treatment well. Our results showed that rhG-CSF has an important role in decreasing period of neutropenia maintaining chemotherapy schedule and allowing patients to receive full doses of chemotherapy on time. [Journal of Turgut Özal Medical Center 1998;5(1):24-29]
The aim of this study was to evaluate the effectiveness of recombinant granulocyte colony stimulating factor (rhG-CSF) administered following cytotoxic chemotherapy in Hodgkin's disease. Total number of 26 courses of rhG-CSF were applied in 19 patients with Hodgkin's disease aged 15 to 61 (median 44) years. They received MOPP (Nitrogen Mustard, Vincritine, Procarbazine, Prednisone) chemotherapy every 28 days. rhG-CSF was given at a dose of 5^/kg daily and subcutaneously from day 2nd to 6th day 8th to 20h unless the neutrophil count exceeded 10.000/mm3, in which case rhG-CSF discontinued. The outcome was compared with 24 prognostically similar control patients treated with the same chemotherapy without rhG-CSF. Recovery of granulocyte counts above 1000/mm was significantly faster in the rhG-CSF treated group (3±0.72 days vs 7±0.81 days; p<0.001). The incidence of febrile neutropenia and empiric parenteral antibiotic use were lower in study patients (%36 vs %64 ; p<0.05). But there was no reduction in the incidence of documented infections. Full doses of chemotherapy could be given on time to 26/26 (%100) rhG-CSF patients but to only 18/24 (%75) controls (p<0.01). All patients tolerated cytokine treatment well. Our results showed that rhG-CSF has an important role in decreasing period of neutropenia maintaining chemotherapy schedule and allowing patients to receive full doses of chemotherapy on time. [Journal of Turgut Özal Medical Center 1998;5(1):24-29]
The aim of this study was to evaluate the effectiveness of recombinant granulocyte colony stimulating factor (rhG-CSF) administered following cytotoxic chemotherapy in Hodgkin's disease. Total number of 26 courses of rhG-CSF were applied in 19 patients with Hodgkin's disease aged 15 to 61 (median 44) years. They received MOPP (Nitrogen Mustard, Vincritine, Procarbazine, Prednisone) chemotherapy every 28 days. rhG-CSF was given at a dose of 5^/kg daily and subcutaneously from day 2nd to 6th day 8th to 20h unless the neutrophil count exceeded 10.000/mm3, in which case rhG-CSF discontinued. The outcome was compared with 24 prognostically similar control patients treated with the same chemotherapy without rhG-CSF. Recovery of granulocyte counts above 1000/mm was significantly faster in the rhG-CSF treated group (3±0.72 days vs 7±0.81 days; p<0.001). The incidence of febrile neutropenia and empiric parenteral antibiotic use were lower in study patients (%36 vs %64 ; p<0.05). But there was no reduction in the incidence of documented infections. Full doses of chemotherapy could be given on time to 26/26 (%100) rhG-CSF patients but to only 18/24 (%75) controls (p<0.01). All patients tolerated cytokine treatment well. Our results showed that rhG-CSF has an important role in decreasing period of neutropenia maintaining chemotherapy schedule and allowing patients to receive full doses of chemotherapy on time. [Journal of Turgut Özal Medical Center 1998;5(1):24-29]
Açıklama
[Journal of Turgut Özal Medical Center 1998;5(1):24-29]
Anahtar Kelimeler
G-CSF, Hodgkin hastalığı, nötropeni, enfeksiyon
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Özkalemkaş, F.;Ali, R.;Karaaslan, Y.;Özkocaman, V.;Tunalı, A.;Turgut Özal Tıp Merkezi Dergisi.5 (1) :1998. İnönü Üniversitesi, Malatya.
